Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As a Third-line or Later-line Therapy for Patients with Metastatic Gastric Cancer

NCT06711471 is registered in ClinicalTrials.gov with LIN YANG as lead sponsor.

NCT NCT06711471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06711471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As a Third-line or Later-line Therapy for Patients with Metastatic Gastric Cancer
Lead sponsor
LIN YANG
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2024
Completion date
November 13, 2027
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer adenocarcinoma metastatic